Accelerate Your Ophthalmic Development with Deep Learning Systems and Sophisticated AI Imaging Technologies…

With state-of-the-art AI-assisted technology making retinal imaging 100 times faster, the rapid advancement of technology in ophthalmology, coupled with the strong unmet need for more drugs for retinal diseases, highlights the urgency of continued focus and progress in this space. This need is emphasized by Merck’s recent $3 billion acquisition of EyeBio. In light of this, as we move into 2025 and beyond, there is a real need to re-unite the retinal imaging biomarkers and endpoints community to align efforts and propel the field to new heights.

Time: 8:00 AM – 5:00 PM

Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States

Prices: USD 2599.00 – USD 5097.00

Speakers: Amitha Domalpally, Assistant Professor and Director, University of Wisconsin-Madison, Archana Nigalye, Associate Director Medical, Alexion, Ash Jayagopal, Chief Scientific and Development Officer, Opus Genetics, Brian Levy, Chief Executive Officer, Ocunexus Therapeutics, Cyril Eleftheriou, Principal Scientist, Novartis, and more